 Clodronic Acid
"Clodronic Acid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification.
| Descriptor ID |
D004002
|
| MeSH Number(s) |
D02.705.429.500.200
|
| Concept/Terms |
Clodronic Acid- Clodronic Acid
- Acid, Clodronic
- Dichloromethane Diphosphonate
- Diphosphonate, Dichloromethane
- Dichloromethylenebisphosphonate
- Dichloromethanediphosphonic Acid
- Acid, Dichloromethanediphosphonic
- Dichloromethylene Biphosphonate
- Biphosphonate, Dichloromethylene
- Dichloromethylene Diphosphonate
- Diphosphonate, Dichloromethylene
- Cl2MDP
- Dichloromethanediphosphonate
|
Below are MeSH descriptors whose meaning is more general than "Clodronic Acid".
Below are MeSH descriptors whose meaning is more specific than "Clodronic Acid".
This graph shows the total number of publications written about "Clodronic Acid" by people in this website by year, and whether "Clodronic Acid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 2 | 0 | 2 | | 2012 | 1 | 1 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2023 | 1 | 0 | 1 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Clodronic Acid" by people in Profiles.
-
Ander SE, Davenport BJ, Evans AB, Morrison TE. Systemic Clodronate Liposome Treatment for Depletion of Blood-Contacting Phagocytes and Investigation of Their Role in the Control of Bunyavirus Viremia. Methods Mol Biol. 2025; 2893:285-298.
-
Uchikawa H, Kameno K, Kai K, Kajiwara S, Fujimori K, Uekawa K, Fujiwara Y, Mukasa A, Kim-Mitsuyama S, Hasegawa Y. Pretreatment with Clodronate Improved Neurological Function by Preventing Reduction of Posthemorrhagic Cerebral Blood Flow in Experimental Subarachnoid Hemorrhage. Neurocrit Care. 2023 08; 39(1):207-217.
-
Gralow JR, Barlow WE, Paterson AHG, M'iao JL, Lew DL, Stopeck AT, Hayes DF, Hershman DL, Schubert MM, Clemons M, Van Poznak CH, Dees EC, Ingle JN, Falkson CI, Elias AD, Messino MJ, Margolis JH, Dakhil SR, Chew HK, Dammann KZ, Abrams JS, Livingston RB, Hortobagyi GN. Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. J Natl Cancer Inst. 2020 07 01; 112(7):698-707.
-
Wu FL, Nolan K, Strait AA, Bian L, Nguyen KA, Wang JH, Jimeno A, Zhou HM, Young CD, Wang XJ. Macrophages Promote Growth of Squamous Cancer Independent of T cells. J Dent Res. 2019 07; 98(8):896-903.
-
Osei-Hwedieh DO, Kanias T, Croix CS, Jessup M, Xiong Z, Sinchar D, Franks J, Xu Q, M Novelli E, Sertorio JT, Potoka K, Binder RJ, Basu S, Belanger AM, Kim-Shapiro DB, Triulzi D, Lee JS, Gladwin MT. Sickle Cell Trait Increases Red Blood Cell Storage Hemolysis and Post-Transfusion Clearance in Mice. EBioMedicine. 2016 Sep; 11:239-248.
-
Morgan GJ, Davies FE, Gregory WM, Szubert AJ, Bell SE, Drayson MT, Owen RG, Ashcroft AJ, Jackson GH, Child JA. Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial. Blood. 2012 Jun 07; 119(23):5374-83.
-
Lu L, Faubel S, He Z, Andres Hernando A, Jani A, Kedl R, Edelstein CL. Depletion of macrophages and dendritic cells in ischemic acute kidney injury. Am J Nephrol. 2012; 35(2):181-90.
-
Morgan GJ, Child JA, Gregory WM, Szubert AJ, Cocks K, Bell SE, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross FM, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Wu P, Davies FE. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial. Lancet Oncol. 2011 Aug; 12(8):743-52.
-
Morgan GJ. Can bisphosphonates improve outcomes in patients with newly diagnosed multiple myeloma? Crit Rev Oncol Hematol. 2011 Feb; 77 Suppl 1:S24-30.
-
Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Owen RG, Feyler S, Ashcroft AJ, Ross F, Byrne J, Roddie H, Rudin C, Cook G, Jackson GH, Child JA. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010 Dec 11; 376(9757):1989-99.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|